|
000
| 01975nam 2200373zi 4500 |
|---|
| 001 | 9.899807 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20230517145128 |
|---|
| 006 | m o d f |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 210514t20212021onc o f00| 0 eng d |
|---|
| 020 | |a9780660388816 |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH164-320/2021E-PDF |
|---|
| 245 | 00|aGuidance document : |bpatented medicines (notice of compliance) regulations. |
|---|
| 264 | 1|a[Ottawa] : |bHealth Canada = Santé Canada, |c2021. |
|---|
| 264 | 4|c©2021 |
|---|
| 300 | |a1 online resource (36 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Ligne directrice : règlement sur les médicaments brevetés (avis de conformité). |
|---|
| 500 | |aIssued also in HTML format. |
|---|
| 500 | |a"Effective date: 2021/05/11." |
|---|
| 520 | |a"This guidance document provides information regarding the administration of the PM (NOC) Regulations by the Office of Patented Medicines and Liaison (OPML) within the Office of Submissions and Intellectual Property (OSIP), Resource Management and Operations Directorate (RMOD), Health Canada. It is applicable to drugs that receive a notice of compliance (NOC), including pharmaceutical, biological, radiopharmaceutical and veterinary drugs"--page 7. |
|---|
| 650 | 0|aPatent medicines|zCanada. |
|---|
| 650 | 0|aPharmaceutical policy|zCanada. |
|---|
| 710 | 1 |aCanada. |bHealth Canada, |eissuing body. |
|---|
| 775 | 08|tLignes directrice : |w(CaOODSP)9.899808 |
|---|
| 795 | |tGuidance document |w9.854770 |
|---|
| 856 | 40|qPDF|s393 KB|uhttps://publications.gc.ca/collections/collection_2021/sc-hc/H164-320-2021-eng.pdf |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/patented-medicines/notice-compliance-regulations.html |
|---|